JP2005521632A - 形質導入造血前駆細胞の生産 - Google Patents
形質導入造血前駆細胞の生産 Download PDFInfo
- Publication number
- JP2005521632A JP2005521632A JP2003512371A JP2003512371A JP2005521632A JP 2005521632 A JP2005521632 A JP 2005521632A JP 2003512371 A JP2003512371 A JP 2003512371A JP 2003512371 A JP2003512371 A JP 2003512371A JP 2005521632 A JP2005521632 A JP 2005521632A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- nucleic acid
- patient
- foreign nucleic
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 title abstract description 11
- 238000004519 manufacturing process Methods 0.000 title description 12
- 238000000034 method Methods 0.000 claims abstract description 97
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 38
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 29
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 29
- 210000004027 cell Anatomy 0.000 claims description 376
- 108090000623 proteins and genes Proteins 0.000 claims description 100
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 79
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 79
- 108090000994 Catalytic RNA Proteins 0.000 claims description 43
- 102000053642 Catalytic RNA Human genes 0.000 claims description 43
- 108091092562 ribozyme Proteins 0.000 claims description 43
- 238000011282 treatment Methods 0.000 claims description 34
- 210000001185 bone marrow Anatomy 0.000 claims description 25
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 22
- 238000002617 apheresis Methods 0.000 claims description 20
- 238000002560 therapeutic procedure Methods 0.000 claims description 20
- 230000037396 body weight Effects 0.000 claims description 19
- 210000000777 hematopoietic system Anatomy 0.000 claims description 19
- 230000000840 anti-viral effect Effects 0.000 claims description 16
- 230000036436 anti-hiv Effects 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 15
- 210000004698 lymphocyte Anatomy 0.000 claims description 13
- 238000001415 gene therapy Methods 0.000 claims description 10
- 230000003394 haemopoietic effect Effects 0.000 claims description 10
- 210000002798 bone marrow cell Anatomy 0.000 claims description 9
- 210000004976 peripheral blood cell Anatomy 0.000 claims description 9
- 230000000692 anti-sense effect Effects 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 230000003834 intracellular effect Effects 0.000 claims description 7
- 238000011529 RT qPCR Methods 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims 6
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims 2
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 239000000047 product Substances 0.000 description 39
- 238000005406 washing Methods 0.000 description 34
- 210000001744 T-lymphocyte Anatomy 0.000 description 32
- 230000001225 therapeutic effect Effects 0.000 description 32
- 108020004414 DNA Proteins 0.000 description 25
- 241000725303 Human immunodeficiency virus Species 0.000 description 22
- 210000002540 macrophage Anatomy 0.000 description 22
- 230000026683 transduction Effects 0.000 description 22
- 238000010361 transduction Methods 0.000 description 22
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 18
- 230000001177 retroviral effect Effects 0.000 description 15
- 241000700605 Viruses Species 0.000 description 13
- 210000005259 peripheral blood Anatomy 0.000 description 13
- 239000011886 peripheral blood Substances 0.000 description 13
- 229930193140 Neomycin Natural products 0.000 description 11
- 238000004113 cell culture Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 229960004927 neomycin Drugs 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 238000004088 simulation Methods 0.000 description 11
- 208000031886 HIV Infections Diseases 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- 108010056030 retronectin Proteins 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 108091006905 Human Serum Albumin Proteins 0.000 description 9
- 102000008100 Human Serum Albumin Human genes 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 108091027757 Deoxyribozyme Proteins 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 230000003197 catalytic effect Effects 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 238000013178 mathematical model Methods 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000001541 thymus gland Anatomy 0.000 description 8
- 241001430294 unidentified retrovirus Species 0.000 description 8
- 108091093088 Amplicon Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 7
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 7
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 7
- 230000009097 homeostatic mechanism Effects 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 230000003321 amplification Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
- 208000037357 HIV infectious disease Diseases 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 5
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000009987 spinning Methods 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 108700004027 tat Genes Proteins 0.000 description 5
- 101150098170 tat gene Proteins 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000013925 CD34 antigen Human genes 0.000 description 4
- 108050003733 CD34 antigen Proteins 0.000 description 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102000036693 Thrombopoietin Human genes 0.000 description 4
- 108010041111 Thrombopoietin Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 108010006260 pegylated granulocyte colony-stimulating factor Proteins 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 3
- 241000204031 Mycoplasma Species 0.000 description 3
- 102000007327 Protamines Human genes 0.000 description 3
- 108010007568 Protamines Proteins 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000009520 phase I clinical trial Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229950008679 protamine sulfate Drugs 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 238000002944 PCR assay Methods 0.000 description 2
- 101710149951 Protein Tat Proteins 0.000 description 2
- 241000251131 Sphyrna Species 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000004296 naive t lymphocyte Anatomy 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101710088235 Envelope glycoprotein C homolog Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 101710149136 Protein Vpr Proteins 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011198 co-culture assay Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000011991 general safety test Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical group [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 238000013190 sterility testing Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30428301P | 2001-07-10 | 2001-07-10 | |
| US34339201P | 2001-10-22 | 2001-10-22 | |
| PCT/US2002/021713 WO2003006612A2 (en) | 2001-07-10 | 2002-07-10 | Production of transduced hematopoietic progenitor cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005521632A true JP2005521632A (ja) | 2005-07-21 |
| JP2005521632A5 JP2005521632A5 (enExample) | 2006-01-05 |
Family
ID=26973926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003512371A Withdrawn JP2005521632A (ja) | 2001-07-10 | 2002-07-10 | 形質導入造血前駆細胞の生産 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20030082158A1 (enExample) |
| EP (1) | EP1418814A4 (enExample) |
| JP (1) | JP2005521632A (enExample) |
| KR (1) | KR20040084885A (enExample) |
| CN (1) | CN1551728A (enExample) |
| BR (1) | BR0211066A (enExample) |
| CA (1) | CA2453187A1 (enExample) |
| IL (1) | IL159777A0 (enExample) |
| WO (1) | WO2003006612A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005528319A (ja) * | 2001-07-10 | 2005-09-22 | ジョンソン・アンド・ジョンソン・リサーチ・プロプライエタリー・リミテッド | 造血前駆細胞を遺伝的に改変する方法及び改変された細胞の使用 |
| US7994144B2 (en) | 2001-07-10 | 2011-08-09 | Johnson & Johnson Research Pty, Limited | Process for the preparation of a composition of genetically modified hematopoietic progenitor cells |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020058636A1 (en) * | 1994-09-21 | 2002-05-16 | Geoffrey P. Symonds | Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
| US7799324B2 (en) | 2001-12-07 | 2010-09-21 | Geron Corporation | Using undifferentiated embryonic stem cells to control the immune system |
| GB2399572B (en) * | 2001-12-07 | 2006-06-07 | Robarts Res Inst | Hematopoietic cells from human embryonic stem cells |
| WO2004041220A2 (en) * | 2002-11-06 | 2004-05-21 | L'oreal | Composition containing a semi-crystalline polymer and a pasty fatty substance |
| FR2846554B1 (fr) * | 2002-11-06 | 2007-02-09 | Oreal | Composition contenant un polymere semi-cristallin et un corps gras pateux |
| GB0410130D0 (en) * | 2004-05-06 | 2004-06-09 | Molmed Spa | Cell preparation |
| WO2012074068A1 (ja) | 2010-12-01 | 2012-06-07 | 日産化学工業株式会社 | ピラゾール化合物による造血幹細胞の製造方法 |
| US11697799B2 (en) | 2019-04-15 | 2023-07-11 | Ossium Health, Inc. | System and method for extraction and cryopreservation of bone marrow |
| EP4181675A4 (en) | 2020-07-18 | 2024-04-24 | Ossium Health, Inc. | PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION |
| CN116583594B (zh) | 2020-10-14 | 2025-05-23 | 奥瑟姆健康公司 | 用于骨髓的提取和低温保藏的系统和方法 |
| WO2022133282A1 (en) | 2020-12-18 | 2022-06-23 | Ossium Health, Inc. | Methods of cell therapies |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5500357A (en) * | 1990-11-02 | 1996-03-19 | Agency Of Industrial Science & Technology, Ministry Of International Trade & Industry | RNA transcription system using novel ribozyme |
| US5525468A (en) * | 1992-05-14 | 1996-06-11 | Ribozyme Pharmaceuticals, Inc. | Assay for Ribozyme target site |
| US5693535A (en) * | 1992-05-14 | 1997-12-02 | Ribozyme Pharmaceuticals, Inc. | HIV targeted ribozymes |
| US5911983A (en) * | 1992-06-26 | 1999-06-15 | University Of Pittsburgh | Gene therapy for Gaucher disease using retroviral vectors |
| US5712384A (en) * | 1994-01-05 | 1998-01-27 | Gene Shears Pty Ltd. | Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
| US20020058636A1 (en) * | 1994-09-21 | 2002-05-16 | Geoffrey P. Symonds | Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
| ES2358187T3 (es) * | 2001-07-10 | 2011-05-06 | JOHNSON & JOHNSON RESEARCH PTY LIMITED | Procedimientos para la modificación genética de las células progenitoras hematopoyéticas y utilizaciones de las células modificadas. |
| KR101015913B1 (ko) * | 2001-07-10 | 2011-02-23 | 존슨 앤드 존슨 리서치 피티와이 리미티드 | 조혈모세포의 유전적 변이 치료 방법 및 변이 세포의 용도 |
-
2002
- 2002-07-10 KR KR10-2004-7000432A patent/KR20040084885A/ko not_active Withdrawn
- 2002-07-10 EP EP02749878A patent/EP1418814A4/en not_active Withdrawn
- 2002-07-10 WO PCT/US2002/021713 patent/WO2003006612A2/en not_active Ceased
- 2002-07-10 CN CNA028174879A patent/CN1551728A/zh active Pending
- 2002-07-10 CA CA002453187A patent/CA2453187A1/en not_active Abandoned
- 2002-07-10 US US10/192,058 patent/US20030082158A1/en not_active Abandoned
- 2002-07-10 JP JP2003512371A patent/JP2005521632A/ja not_active Withdrawn
- 2002-07-10 BR BRPI0211066-0A patent/BR0211066A/pt not_active IP Right Cessation
- 2002-07-10 IL IL15977702A patent/IL159777A0/xx unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005528319A (ja) * | 2001-07-10 | 2005-09-22 | ジョンソン・アンド・ジョンソン・リサーチ・プロプライエタリー・リミテッド | 造血前駆細胞を遺伝的に改変する方法及び改変された細胞の使用 |
| US7994144B2 (en) | 2001-07-10 | 2011-08-09 | Johnson & Johnson Research Pty, Limited | Process for the preparation of a composition of genetically modified hematopoietic progenitor cells |
Also Published As
| Publication number | Publication date |
|---|---|
| US20030082158A1 (en) | 2003-05-01 |
| BR0211066A (pt) | 2006-08-29 |
| CN1551728A (zh) | 2004-12-01 |
| KR20040084885A (ko) | 2004-10-06 |
| IL159777A0 (en) | 2004-06-20 |
| EP1418814A4 (en) | 2006-10-11 |
| CA2453187A1 (en) | 2003-01-23 |
| WO2003006612A2 (en) | 2003-01-23 |
| EP1418814A2 (en) | 2004-05-19 |
| WO2003006612A3 (en) | 2003-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7776595B2 (en) | Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells | |
| Macpherson et al. | Long‐term survival and concomitant gene expression of ribozyme‐transduced CD4+ T‐lymphocytes in HIV‐infected patients | |
| AU2002316640A1 (en) | Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells | |
| US20130344040A1 (en) | Process for the preparation of a composition of genetically modified hematopoietic progenitor cells | |
| JPH08510134A (ja) | Ｈｉｖ感染およびエイズを対象としたリボザイム遺伝子治療 | |
| JP2005521632A (ja) | 形質導入造血前駆細胞の生産 | |
| Ngok et al. | Clinical gene therapy research utilizing ribozymes: application to the treatment of HIV/AIDS | |
| Poznansky et al. | Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells and monocytes derived from CD34+ cells transduced with an intracellular antibody directed against human immunodeficiency virus type 1 Tat | |
| US20060051866A1 (en) | Means of producing and utilising a population of disease specific cytotoxic t-lymphocytes | |
| Bollard et al. | Gene marking studies of hematopoietic cells | |
| AU2002320365A1 (en) | Production of transduced hematopoietic progenitor cells | |
| WO1995006744A2 (en) | Methods of suppressing immune response by gene therapy | |
| HK1065074B (en) | Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells | |
| Ho et al. | Ribozyme Gene Therapy Targeting Stem Cells for Human Immunodeficiency Virus Infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050708 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050708 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20071127 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080826 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081126 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081203 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081226 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090109 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20090126 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20090126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090126 |